UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

UBS analyst Michael Yee has reaffirmed a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) and increased the price target from $585 to $615. This adjustment reflects a positive outlook for the company's performance in the market.